Telos Corporation (TLS) Stock Message Board

Play Episode

7min

Proactive - Interviews for investors

BluGlass talks quantum sensing & commercial wins

BluGlass Head of Corporate and Investor Relations Stefanie Winwood talked with Proactive at the AIM's Small and Midcap Conference about the company’s work in gallium nitride (GaN) laser technology and its growing role in quantum sensing, computing, and defense applications. Winwood explained that gallium nitride is a compound semiconductor that can conduct electrons significantly faster than traditional silicon. BluGlass is one of a few companies globally producing visible lasers using GaN, a technology that is crucial in precision applications such as post-GPS navigation and quantum computing. “BluGlass is leading the market in the precision applications and these precision applications are the ones that are growing more rapidly,” Winwood said. The company works with large clients such as the US Department of Defense and major semiconductor players like General Electric and Coherent. BluGlass has recently secured contracts worth USD 6 million and aims to build long-term, revenue-generating relationships through projects that can lead to multi-decade manufacturing deals. In addition to commercial traction, BluGlass has strengthened its leadership with the appointment of industry veterans, including Nobel Laureate Shuji Nakamura. The company also recently demonstrated a world-record performance combining power and precision for quantum use cases. #BluGlass #QuantumComputing #GaNtechnology #GalliumNitride #Semiconductors #QuantumSensing #DefenseTech #LaserTechnology #InvestorUpdates #TechInnovation

Proactive - Interviews for investors

COSOL Sees U.S. market as key growth driver

COSOL Limited Managing Director Scott McGowan talked with Proactive at AIM's Small and Midcap Conference about the company’s role in driving operational efficiency across asset-intensive industries. COSOL Limited works with organisations in mining, oil and gas, utilities, and public infrastructure to enhance the performance of their physical assets. McGowan explained the company’s core service as unlocking value by helping clients reduce costs through better asset management. “We look at ways that we can save them real dollars to be able to manage that asset more effectively,” he said. The company’s client list includes major names such as Glencore, Rio Tinto, BHP, and several government departments. COSOL provides the systems and processes behind the scenes to manage these organisations’ equipment and facilities, potentially impacting hundreds of millions in operational costs. Even a 2–3% improvement, McGowan said, “makes a significant difference to their bottom line.” COSOL has grown revenue from AUD 30 million to over AUD 110 million since listing. It is now targeting organic growth in the mid-teens and exploring earnings-accretive acquisitions. McGowan also highlighted COSOL’s presence in the U.S., describing it as the company’s largest potential market, where current operations may be expanded through acquisition. #COSOL #ASXStocks #ScottMcGowan #AssetManagement #MiningTech #Utilities #PublicInfrastructure #OperationalEfficiency #DataSolutions #IndustrialSoftware #GrowthStocks #USExpansion #InvestingInTech -

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

Fineqia International CEO unveils first DeFi yield ETP

Fineqia International Inc (CSE:FNQ, OTC:FNQQF) CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell

Followers	0	Posters	1
Posts (Today)	0	Posts (Total)	3
Created	08/14/23	Type	Free
Moderators

Volume:	122,807
Day Range:	2.34 - 2.475
Last Trade Time:	2:01:45 PM EDT

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Telos Corporation (TLS)

TLS Detailed Quote

TLS Latest News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Telos Corporation (TLS)

TLS Latest News

Go Ad-Free